SCHEMBL19948

SCHEMBL19948

N[C@@H](C=O)[C@@H](OP(=O)(O)O)[C@H](O)[C@H](O)CO

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MPI P34949 1/20 0.36
USP2 O75604 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
PAX8 Q06710 1/20 0.33
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165933 1.00 MPI (0.36) MPIUSP2SLCO1B1PAX8LMNA
SCHEMBL7155133 1.00 MPI (0.36) MPIUSP2SLCO1B1PAX8LMNA
SCHEMBL181949 1.00 MPI (0.36) MPIUSP2SLCO1B1PAX8LMNA
SCHEMBL10699689 0.88 MPI (0.33) MPIUSP2SLCO1B1PAX8
SCHEMBL9078408 0.88 MPI (0.33) MPIUSP2SLCO1B1PAX8
SCHEMBL705391 0.87 PAX8 (0.36) MPIUSP2SLCO1B1PAX8
SCHEMBL5351083 0.83 ITPR3 (0.31)
SCHEMBL177758 0.83 MPI (0.46) MPILMNAL3MBTL1TDP1
SCHEMBL5972505 0.83 MPI (0.46) MPILMNAL3MBTL1TDP1
SCHEMBL1922060 0.83 MPI (0.46) MPILMNAL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085839-A1 COMPOSITION AND METHOD FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-04-30 WO claimed
CN-222349015-U Device for producing D-psicose by utilizing fructose solution 东台市浩瑞生物科技有限公司 2025-01-14 CN claimed
CN-112851723-B Continuous preparation device and process for glucosamine sulfate or phosphate compound 厦门海洋本草绿色科技有限公司 2024-12-27 CN claimed
CN-118389625-A Method for co-producing glucosamine hydrochloride and D-psicose from fructose solution 诸城市浩天生物科技有限公司 2024-07-26 CN claimed
CN-117586443-A Polyacrylamide glucosamine ester, and preparation method and application thereof 中国科学院福建物质结构研究所 2024-02-23 CN claimed
WO-2023219437-A1 METHOD FOR PRODUCING LACTO-N-TETRAOSE AND LACTO-N-NEOTETRAOSE USING CORYNEBACTERIUM GLUTAMICUM (주)에이피테크놀로지 2023-11-16 WO claimed
CN-116323927-A Cell production of di-and/or oligosaccharides 因比奥斯公司 2023-06-23 CN claimed
CN-115804451-A Composition beneficial to increase of bone density and application of composition in food 广州欣盛通健康管理科技有限公司 2023-03-17 CN claimed
CN-112458034-B Recombinant escherichia coli constructed by genetic engineering and method for biologically synthesizing 6' -sialyllactose 南开大学 2023-01-24 CN claimed
CN-112280727-B Recombinant escherichia coli for synthesizing lactyl-N-trisaccharide and construction method and application thereof 江南大学 2022-12-30 CN claimed
US-6911326-B1 GlmU polypeptide and DNA encoding the polypeptide KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-06-28 US claimed
WO-2005056570-A2 PRODUCTION OF AMINO SUGARS CARGILL, INC. (US) 2005-06-23 WO claimed
US-20050014720-A1 Process for the preparation of glucosamine salts BIOBERICA, S.A. (ES) 2005-01-20 US claimed
US-20040185035-A1 Dietary supplements and methods for treating pain and inflammation MELALEUCA, INC., AN IDAHO CORPORATION 2004-09-23 US claimed
EP-1455800-A1 PROCESS FOR THE PREPARATION OF GLUCOSAMINE SALTS BIOIBERICA, S.A. (ES) 2004-09-15 EP claimed
US-6713096-B2 FOR REDUCING PAIN, INFLAMMATION, STIFFNESS, OR DISCOMFORT IN A MAMMAL MELALEUCA, INC. 2004-03-30 US claimed
US-20030143292-A1 For reducing pain, inflammation, stiffness, or discomfort in a mammal MELALEUCA, INC. 2003-07-31 US claimed
WO-2003053448-A1 PROCESS FOR THE PREPARATION OF GLUCOSAMINE SALTS BIOIBERICA, S.A. (ES) 2003-07-03 WO claimed
EP-1234882-A1 GlmU POLYPEPTIDE AND DNA ENCODING THE POLYPEPTIDE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-28 EP claimed
US-20020064836-A1 PROCESSES FOR PRODUCING SUGAR NUCLEOTIDES AND COMPLEX CARBOHYDRATES KYOWA HAKKO BIO CO., LTD. (JP) 2002-05-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030143292-A1 For reducing pain, inflammation, stiffness, or discomfort in a mammal TNF, IL6, IL1B MPI 2440/4885USP2 3641/4885SLCO1B1 2840/4885
US-20040185035-A1 Dietary supplements and methods for treating pain and inflammation IL6, TNF, IL1B MPI 2507/4885USP2 3164/4885SLCO1B1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.